BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema
Share: — —EMPOWER Patient Services providing streamlined, single point of contact access to therapy and reimbursement support— RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that oral, once-daily ORLADEYO™ (berotralstat) is now available for shipment to patients with a prescription in the United States. ORLADEYO was approved by the U.S. Food and Drug Administration (FDA) on December 3, 2020 for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 ...
Source: benzinga.com